Information for Members of the Public

The information within this section of the website is intended for members of the public. Here you will find general information about ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD).1-5

Entyvio (vedolizumab) is a treatment for adults with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease, two types of inflammatory bowel disease (IBD).

Please click on the relevant link if you have been Prescribed Entyvio (vedolizumab), or are a Healthcare Professional in England, Scotland or Wales .

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the Patient Information Leaflet.

You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

By reporting side effects, you can help provide more information on the safety of this medicine.